Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Front Oncol ; 12: 920990, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35875128

RESUMEN

Crizotinib is a tyrosine kinase inhibitor that has been found to be effective in the treatment of c-ros oncogene 1-positive non-small cell lung cancer. Although this targeted agent for treating cancer has shown superiority to standard chemotherapy in some ways, this drug has adverse effects, such as the development of renal abscesses. Some associated renal damage may disappear with crizotinib withdrawal. Hence, we present the case of a 58-year-old man with non-small cell lung cancer on crizotinib therapy who developed bilateral renal abnormal space-occupying lesions, successively which were difficult to identify using various imaging methods; even PET-CT highly suspected the right renal masses as malignant. Finally, the right renal lesions were confirmed as renal abscesses by postoperative pathology. The left renal lesion was considered as renal cysts through the lesion disappearing after crizotinib withdrawal. There have been very few reports in this respect, especially proved by various methods and confirmed by postoperative pathology. It is important to recognize this drug-related complication in order to avoid incorrect diagnosis and inadequate therapy. It is necessary to monitor renal changes after taking crizotinib.

2.
Medicine (Baltimore) ; 101(29): e29251, 2022 Jul 22.
Artículo en Inglés | MEDLINE | ID: mdl-35866803

RESUMEN

This study aimed to evaluate the efficacy and safety of iodine 125 (125I) radioactive seed implantation for small cell lung cancer at the limited stage of relapse as second line therapy. We collected 6 patients with recurred limited stage small cell lung cancer, who got pathological diagnosis after a bronchoscopic biopsy and then received standard first line treatment, combined chemotherapy and radiotherapy, including prophylactic cranial irradiation. These recurred small cell lung cancer patients got 125I seed implantation treatment as second line therapy, if the treatment not good responsive or the disease got rapid progress, we used the second line chemotherapy as salvage treatment. Clinical data of these patients were collected and short-term effects were observed. The follow-up period lasted for 42 months. All the patients tolerated the procedure of 125I radioactive seed implantation very well. We followed up the patients to 42 months. Five patients got complete remission and 1 patient got partial remission at 1 month after implantation. The objective response rate was 100%. The median survival time was 26 months. And median progression-free survival was 12 months after 125I treatment. And about the complications, 1 patient suffered from the light aerothorax, 1 patient had a little hemoptysis. Our study showed that 125I seed implantation as second line regimen in small cell lung cancer that recurred locally after first line treatment was effective and safe. That could improve the overall survival and progression-free survival only comparing to the second line chemotherapy. Therefore 125I seed implantation as brachytherapy protocol is a promising method and can be applied as second line treatment to control the locally recurred small cell lung cancer.


Asunto(s)
Braquiterapia , Neoplasias Pulmonares , Carcinoma Pulmonar de Células Pequeñas , Braquiterapia/métodos , Humanos , Radioisótopos de Yodo/uso terapéutico , Neoplasias Pulmonares/tratamiento farmacológico , Recurrencia Local de Neoplasia/tratamiento farmacológico , Carcinoma Pulmonar de Células Pequeñas/tratamiento farmacológico , Carcinoma Pulmonar de Células Pequeñas/radioterapia , Tomografía Computarizada por Rayos X/métodos , Resultado del Tratamiento
3.
Sensors (Basel) ; 20(4)2020 Feb 13.
Artículo en Inglés | MEDLINE | ID: mdl-32070006

RESUMEN

As one of the critical components of high-speed trains, the running gears system directly affects the operation performance of the train. This paper proposes a state-degradation-oriented method for fault diagnosis of an actual running gears system based on the Wiener state degradation process and multi-sensor filtering. First of all, for the given measurements of the high-speed train, this paper considers the information acquisition and transfer characteristics of composite sensors, which establish a distributed topology for axle box bearing. Secondly, a distributed filtering is built based on the bilinear system model, and the gain parameters of the filter are designed to minimize the mean square error. For a better presentation of the degradation characteristics in actual operation, this paper constructs an improved nonlinear model. Finally, threshold is determined based on the Chebyshev's inequality for a reliable fault diagnosis. Open datasets of rotating machinery bearings and the real measurements are utilized in the case studies to demonstrate the effectiveness of the proposed method. Results obtained in this paper are consistent with the actual situation, which validate the proposed methods.

4.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 19(1): 15-8, 2011 Feb.
Artículo en Chino | MEDLINE | ID: mdl-21362213

RESUMEN

This study was aimed to explore the expression of erythropoietin receptor (EPOR) on acute leukemia cells and its clinical significance. Bone marrow of 40 patients with acute leukemia (AL) and 24 patients with normal bone marrow as control group were collected. Samples came from outpatients and inpatients in our hospital. EPOR mRNA was detected by reverse transcription-PCR. The results showed that there was EPOR expression on AL cells, the expression rate was 57.5%, and the average expression level (Gray value) was 0.3549 ± 0.2800, but both were lower than that in control group (p < 0.05). There was no significant statistic difference of expression rate between acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) (p > 0.05), and expression level of AML EPOR was higher than that of ALL (p < 0.05). It is concluded that there is EPOR expression on AL cells, while the expression rate and expression level are lower than those in control group (p < 0.05). There is no significant statistic difference of the expression rate between AML and ALL (p > 0.05), and the expression level of AML EPOR is higher than that of ALL (p < 0.05).


Asunto(s)
Leucemia Mieloide Aguda/genética , Receptores de Eritropoyetina/genética , Estudios de Casos y Controles , Humanos , Leucemia Mieloide Aguda/metabolismo , ARN Mensajero/genética , Receptores de Eritropoyetina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...